Entera Bio
$1.21
45
-$0.03-2.42% Today
Statistics
Day High
1.24
Day Low
1.22
52W High
3.14
52W Low
1
Volume
11,000
Avg. Volume
-
Mkt Cap
55.49M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
7AugExpected
Expected EPS
-0.08
Actual EPS
N/A
Financials
-5,271.27%Profit Margin
Unprofitable362,000Revenue
-19.08MNet Income
Analyst Ratings
9Average Price Target
The highest estimate is 9.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ENTX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap183.12B
Abbvie
ABBV
Mkt Cap381.1B
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
Pfizer
PFE
Mkt Cap147.62B
Novo Nordisk
NVO
Mkt Cap199.25B
Regeneron Pharmaceuticals
REGN
Mkt Cap66.98B
Vertex Pharmaceuticals
VRTX
Mkt Cap110.28B
Gilead Sciences
GILD
Mkt Cap166.82B
About
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Show more...
CEO
Ms. Miranda J. Toledano M.B.A.
Employees
18
Country
Israel
ISIN
IL0011429839
Listings
0 Comments
Share your thoughts
FAQ
What is Entera Bio stock price today?▼
The current price of ENTX is $1.21 USD — it has decreased by -2.42% in the past 24 hours. Watch Entera Bio stock price performance more closely on the chart.
What is Entera Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Entera Bio stocks are traded under the ticker ENTX.
Is Entera Bio stock price growing?▼
ENTX stock has fallen by -4.72% compared to the previous week, the month change is a +8.04% rise, over the last year Entera Bio has showed a -37.95% decrease.
What is Entera Bio market cap?▼
Today Entera Bio has the market capitalization of 55.49M
When is the next Entera Bio earnings date?▼
Entera Bio is going to release the next earnings report on August 07, 2026.
What were Entera Bio earnings last quarter?▼
ENTX earnings for the last quarter are -0.07 USD per share, whereas the estimation was -0.08 USD resulting in a +12.5% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Entera Bio revenue for the last year?▼
Entera Bio revenue for the last year amounts to 362,000 USD.
What is Entera Bio net income for the last year?▼
ENTX net income for the last year is -19.08M USD.
How many employees does Entera Bio have?▼
As of May 26, 2026, the company has 18 employees.
In which sector is Entera Bio located?▼
Entera Bio operates in the Health & Wellness sector.
When did Entera Bio complete a stock split?▼
Entera Bio has not had any recent stock splits.
Where is Entera Bio headquartered?▼
Entera Bio is headquartered in Jerusalem, Israel.